Aslan Pharma of Singapore provided an update on the progress of its three clinical-stage oncology and immunology candidates: • The company signed up K-MASTER to run a 400 patient South Korean Phase Ib/II trial of its lead drug, varlitinib, in patients with metastatic gastric cancer. • ASLAN003 started a four-arm Phase II clinical trial for advanced relapsed/refractory acute myeloid leukemia; • Aslan acquired global rights to ASLAN004 for all indications from CSL in a $780 million deal. Previously, Aslan had global rights only for asthma. Source: China Biotoday
